[{"orgOrder":0,"company":"USV Private Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"||Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"USV Private Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zibotentan","moa":"||Endothelin receptor ET-A","graph1":"Nephrology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"||IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"George Medicines","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Metformin","moa":"||Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase II","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Medicines \/ CUREator","highestDevelopmentStatusID":"8","companyTruncated":"George Medicines \/ CUREator"},{"orgOrder":0,"company":"Amplifier Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Pan-AMPK","graph1":"Endocrinology","graph2":"Phase I","graph3":"Amplifier Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amplifier Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amplifier Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Catholic University of Korea","sponsor":"AstraZeneca | Severance Hospital | Gansu Provincial Hospital | Kyung Hee University Hospital at Gangdong","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Catholic University of Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catholic University of Korea \/ AstraZeneca | Severance Hospital | Gansu Provincial Hospital | Kyung Hee University Hospital at Gangdong","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of Korea \/ AstraZeneca | Severance Hospital | Gansu Provincial Hospital | Kyung Hee University Hospital at Gangdong"},{"orgOrder":0,"company":"AJU Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase I","graph3":"AJU Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AJU Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AJU Pharm \/ Undisclosed"},{"orgOrder":0,"company":"AJU Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase I","graph3":"AJU Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AJU Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AJU Pharm \/ Undisclosed"},{"orgOrder":0,"company":"THPharm Corp.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"THAILAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"THPharm Corp.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"THPharm Corp. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"THPharm Corp. \/ Undisclosed"},{"orgOrder":0,"company":"Bio-innova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"THAILAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bio-innova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bio-innova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-innova \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nectar Lifecare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Nectar Lifecare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nectar Lifecare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nectar Lifecare \/ Undisclosed"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akums Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akums Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mankind Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Equilab International","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Dexa Medica \/ Equilab International","highestDevelopmentStatusID":"1","companyTruncated":"Dexa Medica \/ Equilab International"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"CMG Pharmaceutical CO., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CMG Pharmaceutical CO., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CMG Pharmaceutical CO., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CMG Pharmaceutical CO., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ AstraZeneca"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e4tsklinikum Hamburg-Eppendorf","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Universit\u00e4tsklinikum Hamburg-Eppendorf","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ AstraZeneca"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire Saint Pierre","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Centre Hospitalier Universitaire Saint Pierre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire Saint Pierre \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier Universitaire Saint Pierre \/ AstraZeneca"},{"orgOrder":0,"company":"Steno Diabetes Center Copenhagen","sponsor":"Glostrup University Hospital, Copenhagen | Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"Steno Diabetes Center Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Steno Diabetes Center Copenhagen \/ Glostrup University Hospital, Copenhagen | Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Steno Diabetes Center Copenhagen \/ Glostrup University Hospital, Copenhagen | Novo Nordisk"},{"orgOrder":0,"company":"Steno Diabetes Center Copenhagen","sponsor":"Novo Nordic Foundation | Rigshospitalet | AstraZeneca | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Steno Diabetes Center Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steno Diabetes Center Copenhagen \/ Novo Nordic Foundation | Rigshospitalet | AstraZeneca | Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Steno Diabetes Center Copenhagen \/ Novo Nordic Foundation | Rigshospitalet | AstraZeneca | Bayer AG"},{"orgOrder":0,"company":"University Hospital, Rouen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase II","graph3":"University Hospital, Rouen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Hospital, Rouen \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Rouen \/ AstraZeneca"},{"orgOrder":0,"company":"Mario Negri Institute for Pharmacological Research","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase II","graph3":"Mario Negri Institute for Pharmacological Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mario Negri Institute for Pharmacological Research \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Mario Negri Institute for Pharmacological Research \/ AstraZeneca"},{"orgOrder":0,"company":"University of Palermo","sponsor":"AstraZeneca | University of Catania","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Palermo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Palermo \/ AstraZeneca | University of Catania","highestDevelopmentStatusID":"11","companyTruncated":"University of Palermo \/ AstraZeneca | University of Catania"},{"orgOrder":0,"company":"Ospedale San Martino","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Ospedale San Martino","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ospedale San Martino \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Ospedale San Martino \/ AstraZeneca"},{"orgOrder":0,"company":"Amsterdam UMC, VUmc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Amsterdam UMC, VUmc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amsterdam UMC, VUmc \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Amsterdam UMC, VUmc \/ AstraZeneca"},{"orgOrder":0,"company":"Amsterdam UMC","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"Amsterdam UMC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amsterdam UMC \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Amsterdam UMC \/ ZonMw"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Groningen \/ AstraZeneca"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"AstraZeneca | Dutch Kidney Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ AstraZeneca | Dutch Kidney Foundation","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Center Groningen \/ AstraZeneca | Dutch Kidney Foundation"},{"orgOrder":0,"company":"Slotervaart Hospital","sponsor":"AstraZeneca | Isala | Spaarne Gasthuis","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Slotervaart Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Slotervaart Hospital \/ AstraZeneca | Isala | Spaarne Gasthuis","highestDevelopmentStatusID":"11","companyTruncated":"Slotervaart Hospital \/ AstraZeneca | Isala | Spaarne Gasthuis"},{"orgOrder":0,"company":"Maastricht University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Maastricht University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Maastricht University \/ AstraZeneca"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University Medical Center Groningen \/ AstraZeneca"},{"orgOrder":0,"company":"Anemia Working Group Romania","sponsor":"Sf Ioan Emergency Clinical Hospital, Nephrology and Dialysis Department, Bucharest, Romania | Dr Carol Davila Teaching Hospital of Nephrology Bucharest | Carol Davila University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"ROMANIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"Anemia Working Group Romania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anemia Working Group Romania \/ Sf Ioan Emergency Clinical Hospital, Nephrology and Dialysis Department, Bucharest, Romania | Dr Carol Davila Teaching Hospital of Nephrology Bucharest | Carol Davila University of Medicine and Pharmacy","highestDevelopmentStatusID":"11","companyTruncated":"Anemia Working Group Romania \/ Sf Ioan Emergency Clinical Hospital, Nephrology and Dialysis Department, Bucharest, Romania | Dr Carol Davila Teaching Hospital of Nephrology Bucharest | Carol Davila University of Medicine and Pharmacy"},{"orgOrder":0,"company":"LM Diagn\u00f3sticos S.L.","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SPAIN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LM Diagn\u00f3sticos S.L.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"LM Diagn\u00f3sticos S.L. \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"LM Diagn\u00f3sticos S.L. \/ AstraZeneca"},{"orgOrder":0,"company":"Uppsala University","sponsor":"Uppsala University Hospital | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Uppsala University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uppsala University \/ Uppsala University Hospital | AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Uppsala University \/ Uppsala University Hospital | AstraZeneca"},{"orgOrder":0,"company":"Uppsala University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Uppsala University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uppsala University \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Uppsala University \/ AstraZeneca"},{"orgOrder":0,"company":"Uppsala University","sponsor":"Uppsala University Hospital | Swedish Healthcare Regions | Swedish National Board of Health and Welfare | The Swedish National Diabetes Register","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Uppsala University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uppsala University \/ Uppsala University Hospital | Swedish Healthcare Regions | Swedish National Board of Health and Welfare | The Swedish National Diabetes Register","highestDevelopmentStatusID":"11","companyTruncated":"Uppsala University \/ Uppsala University Hospital | Swedish Healthcare Regions | Swedish National Board of Health and Welfare | The Swedish National Diabetes Register"},{"orgOrder":0,"company":"University of Liverpool","sponsor":"AstraZeneca | Clinical Practice Research Datalink","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Liverpool","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"University of Liverpool \/ AstraZeneca | Clinical Practice Research Datalink","highestDevelopmentStatusID":"11","companyTruncated":"University of Liverpool \/ AstraZeneca | Clinical Practice Research Datalink"},{"orgOrder":0,"company":"University of Dundee","sponsor":"NHS Tayside | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Dundee","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Dundee \/ NHS Tayside | AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Dundee \/ NHS Tayside | AstraZeneca"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"AstraZeneca | NHS Lothian","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Edinburgh \/ AstraZeneca | NHS Lothian","highestDevelopmentStatusID":"1","companyTruncated":"University of Edinburgh \/ AstraZeneca | NHS Lothian"},{"orgOrder":0,"company":"Kinderkrankenhaus auf der Bult","sponsor":"AstraZeneca | Alcedis","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Kinderkrankenhaus auf der Bult","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kinderkrankenhaus auf der Bult \/ AstraZeneca | Alcedis","highestDevelopmentStatusID":"6","companyTruncated":"Kinderkrankenhaus auf der Bult \/ AstraZeneca | Alcedis"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Antaros Medical | Bioventure Hub | 43183 M\u00f6lndal | Sweden","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Antaros Medical | Bioventure Hub | 43183 M\u00f6lndal | Sweden","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Antaros Medical | Bioventure Hub | 43183 M\u00f6lndal | Sweden"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca | Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ AstraZeneca | Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca | Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ AstraZeneca | Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel | Q2 Solutions | PRA Health Sciences | Covance","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Parexel | Q2 Solutions | PRA Health Sciences | Covance","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Parexel | Q2 Solutions | PRA Health Sciences | Covance"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Uppsala University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Uppsala University","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Uppsala University"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca | Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ AstraZeneca | Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Saint Luke's Health System","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Saint Luke's Health System","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Saint Luke's Health System"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb | TIMI Study Group | Hadassah Medical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb | TIMI Study Group | Hadassah Medical Organization","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb | TIMI Study Group | Hadassah Medical Organization"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sequana Medical \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"QATAR","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Gulf Regional Research & Educational Services, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Gulf Regional Research & Educational Services, LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gulf Regional Research & Educational Services, LLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gulf Regional Research & Educational Services, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Scripps Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Scripps Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Scripps Health \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"REMD Biotherapeutics | Juvenile Diabetes Research Foundation | Helmsley Charitable Trust","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ REMD Biotherapeutics | Juvenile Diabetes Research Foundation | Helmsley Charitable Trust","highestDevelopmentStatusID":"7","companyTruncated":"University of California, San Diego \/ REMD Biotherapeutics | Juvenile Diabetes Research Foundation | Helmsley Charitable Trust"},{"orgOrder":0,"company":"University of Miami","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ AstraZeneca"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"AstraZeneca | University of Toronto | Toronto General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Health Network, Toronto \/ AstraZeneca | University of Toronto | Toronto General Hospital","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ AstraZeneca | University of Toronto | Toronto General Hospital"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Sunnybrook Health Sciences Centre | Mount Sinai Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Health Network, Toronto \/ Sunnybrook Health Sciences Centre | Mount Sinai Hospital","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Sunnybrook Health Sciences Centre | Mount Sinai Hospital"},{"orgOrder":0,"company":"Tulane University School of Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Tulane University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tulane University School of Medicine \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Tulane University School of Medicine \/ AstraZeneca"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"University of California, Los Angeles | Brett Boyer Foundation | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johns Hopkins University \/ University of California, Los Angeles | Brett Boyer Foundation | AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Johns Hopkins University \/ University of California, Los Angeles | Brett Boyer Foundation | AstraZeneca"},{"orgOrder":0,"company":"TIMI Study Group","sponsor":"AstraZeneca | Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"TIMI Study Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TIMI Study Group \/ AstraZeneca | Worldwide Clinical Trials","highestDevelopmentStatusID":"11","companyTruncated":"TIMI Study Group \/ AstraZeneca | Worldwide Clinical Trials"},{"orgOrder":0,"company":"University of Michigan","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Michigan \/ AstraZeneca"},{"orgOrder":0,"company":"Saint Luke\u2019s Health System","sponsor":"St. Luke's Hospital, Kansas City | AstraZeneca | George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Saint Luke\u2019s Health System","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saint Luke\u2019s Health System \/ St. Luke's Hospital, Kansas City | AstraZeneca | George Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Saint Luke\u2019s Health System \/ St. Luke's Hospital, Kansas City | AstraZeneca | George Clinical"},{"orgOrder":0,"company":"Saint Luke\u2019s Health System","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Oncology","graph2":"Phase II","graph3":"Saint Luke\u2019s Health System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saint Luke\u2019s Health System \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Saint Luke\u2019s Health System \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Rochester","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Rochester \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Rochester \/ AstraZeneca"},{"orgOrder":0,"company":"University at Buffalo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"University at Buffalo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"University at Buffalo \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"University at Buffalo \/ AstraZeneca"},{"orgOrder":0,"company":"University at Buffalo","sponsor":"Kaleida Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University at Buffalo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University at Buffalo \/ Kaleida Health","highestDevelopmentStatusID":"11","companyTruncated":"University at Buffalo \/ Kaleida Health"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albert Einstein Healthcare Network \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Albert Einstein Healthcare Network \/ Undisclosed"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Pennsylvania \/ Amgen Inc"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University Medical Center \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Vanderbilt University Medical Center \/ AstraZeneca"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Texas Health Science Center at San Antonio \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ AstraZeneca"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Texas Health Science Center at San Antonio \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ AstraZeneca"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"American Diabetes Association | AstraZeneca | National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Texas Health Science Center at San Antonio \/ American Diabetes Association | AstraZeneca | National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at San Antonio \/ American Diabetes Association | AstraZeneca | National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"University of Washington","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Washington \/ AstraZeneca"},{"orgOrder":0,"company":"JAMP PHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"JAMP PHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JAMP PHARMA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"JAMP PHARMA \/ Undisclosed"},{"orgOrder":0,"company":"George Clinical","sponsor":"University Medical Center Groningen | Ground Zero Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"George Clinical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Clinical \/ University Medical Center Groningen | Ground Zero Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"George Clinical \/ University Medical Center Groningen | Ground Zero Pharmaceuticals"},{"orgOrder":0,"company":"Centro de Diabetes Curitiba","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Centro de Diabetes Curitiba","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centro de Diabetes Curitiba \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Centro de Diabetes Curitiba \/ AstraZeneca"},{"orgOrder":0,"company":"University of Campinas, Brazil","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Campinas, Brazil","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Campinas, Brazil \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Campinas, Brazil \/ AstraZeneca"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BRAZIL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Frank Ruschitzka","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Frank Ruschitzka","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Frank Ruschitzka \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Frank Ruschitzka \/ AstraZeneca"},{"orgOrder":0,"company":"Christopher Bell","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Christopher Bell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Christopher Bell \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Christopher Bell \/ AstraZeneca"},{"orgOrder":0,"company":"Christopher Bell","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Christopher Bell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Christopher Bell \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Christopher Bell \/ AstraZeneca"},{"orgOrder":0,"company":"Hiddo Lambers Heerspink","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase II","graph3":"Hiddo Lambers Heerspink","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hiddo Lambers Heerspink \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Hiddo Lambers Heerspink \/ AstraZeneca"},{"orgOrder":0,"company":"Christopher Bell","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Christopher Bell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Christopher Bell \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Christopher Bell \/ AstraZeneca"},{"orgOrder":0,"company":"M.H.H. Kramer","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"M.H.H. Kramer","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M.H.H. Kramer \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"M.H.H. Kramer \/ AstraZeneca"},{"orgOrder":0,"company":"Woman's","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Woman's","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Woman's \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Woman's \/ AstraZeneca"},{"orgOrder":0,"company":"Mari\u00eblle Scheffer","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mari\u00eblle Scheffer","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mari\u00eblle Scheffer \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Mari\u00eblle Scheffer \/ AstraZeneca"},{"orgOrder":0,"company":"Han Xu","sponsor":"UnitedHealthcare","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Han Xu","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Han Xu \/ UnitedHealthcare","highestDevelopmentStatusID":"9","companyTruncated":"Han Xu \/ UnitedHealthcare"},{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"German Federal Ministry of Education and Research | German Center for Diabetes Research | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital T\u00fcbingen \/ German Federal Ministry of Education and Research | German Center for Diabetes Research | AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital T\u00fcbingen \/ German Federal Ministry of Education and Research | German Center for Diabetes Research | AstraZeneca"},{"orgOrder":0,"company":"Cambridge University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cambridge University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cambridge University \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cambridge University \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Biocard","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Biocard","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Biocard"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Mascot Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mascot Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Mascot Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mascot Health \/ Undisclosed"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sequana Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Dapagliflozin
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
